Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer

More than 3000 clinical trials are evaluating the clinical activity of the PD-1 checkpoint inhibitors as monotherapies and in combinations with other cancer therapies [1]. The PD-1 checkpoint inhibitors are remarkable for their clinical activities in shrinking tumors across a wide range of tumor typ...

Descripción completa

Detalles Bibliográficos
Autor principal: Schmidt, Emmett V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323091/
https://www.ncbi.nlm.nih.gov/pubmed/30374524
http://dx.doi.org/10.1007/s00281-018-0714-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323091/
https://www.ncbi.nlm.nih.gov/pubmed/30374524
http://dx.doi.org/10.1007/s00281-018-0714-9

Ejemplares similares